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Abstract
Background: Experimental allergic encephalomyelitis (EAE) is the most commonly used experimental animal model
for human multiple sclerosis (MS) that has been used so far to study the acute and remission-relapsing phases of
the disease. Despite the vast literature on neuroinflammation onset and progression in EAE, important questions
are still open regarding in particular the early asymptomatic phase between immunization and clinical onset.
Methods: In this study, we performed a time-course investigation of neuroinflammation and demyelination
biomarkers in the spinal cord (SC), cerebrospinal fluid (CSF), and blood in EAE induced in dark agouti (DA) female
rats compared to the controls and adjuvant-injected rats, using high-throughput technologies for gene expression
and protein assays and focusing on the time-course between immunization, clinical onset (1, 5, 8 days post-immunization
(DPI)), and progression (11 and 18 DPI). The expression profile of 84 genes related to T cell activation/signaling, adaptive
immunity, cytokine/chemokine inflammation, demyelination, and cellular stress were analyzed in the tissue; 24 cytokines
were measured in the CSF and plasma.
Results: The macrophage colony-stimulating factor (CSF1) was the first up-regulated protein as far as 1 DPI, not only in
blood but also in CSF and SC. A treatment with GW2580, a selective CSF1R inhibitor, slowed the disease
progression, significantly reduced the severity, and prevented the relapse phase. Moreover, both pro-inflammatory
(IL-1β, TNF-α) and anti-inflammatory cytokines (IL-5, IL-10, VEGF) were up-regulated starting from 8 DPI. Myelin genes
were down-regulated starting from 8 DPI, especially MAL, MBP, and PMP22 while an opposite expression profile was
observed for inflammation-related genes, such as CXCL11 and CXCL10.
Conclusions: This early cytokine and chemokine regulation indicates that novel biomarkers and therapeutic options
could be explored in the asymptomatic phase of EAE. Overall, our findings provide clear evidence that CSF1R signaling
regulates inflammation in EAE, supporting therapeutic targeting of CSF1R in MS.
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Background
Inflammation and demyelination are the primary patho-
logical events in multiple sclerosis (MS), the most diffuse
inflammatory demyelinating disease of the central ner-
vous system (CNS) [1]. The progressive failure of remye-
lination leads to the cumulative loss of axons, gray
matter atrophy, and the prevalent neurodegeneration
responsible for chronic disability and cognitive defects
[2]. Despite the intensive efforts and the major progress
achieved in understanding the inflammatory process and
pathogenetic mechanisms within this heterogeneous dis-
ease entity to date, the exact pathophysiological process
of MS remains elusive.
Both humoral and the cell-mediated immune reactions
having peripheral macrophages and central microglia as
key players take part in the neural-immune mechanisms
underlying MS [3]. Indeed, MS pathogenesis has been
believed to be derived from autoreactive lymphocytes
(T/B cells) and a plethora of macrophages recruited
from the periphery. Both cell classes are able to cross
the blood–brain barrier (BBB) [4] and to engage micro-
glia, the resident immune cells in the CNS [5], ultimately
leading to severe demyelination and neuronal degener-
ation. Cytokines and chemokines play a key role in these
processes by regulating cell migration, proliferation, and
activation of resident and infiltrating cells [6].
An important contribution to MS studies has been
made by experimental allergic encephalomyelitis (EAE),
the most widely used animal model for MS [7], in which
the interaction between a variety of immunopathological
and neuropathological mechanisms affords an approxi-
mation of the key pathological features of MS pathology,
including inflammation and immune reaction, demyelin-
ation, axonal loss, and gliosis [8, 9]. EAE has been also
used to develop and validate all approved therapies for
MS [10], thus confirming the good correlation between
animal and human pathology [11, 12].
In particular, the EAE model allows a hitherto poorly
studied phase of the disease to be investigated, i.e., the
preclinical asymptomatic phase. This time window could
be particularly interesting for the discovery of novel early
biomarkers and novel therapeutic target. According to re-
cent reports, in the MS murine model, a significant T cell
mobilization was observed at 2 days post-immunization
(DPI), thus an asymptomatic stage of the disease [13].
Furthermore, a transient vessel leak in the cortical gray
matter has been described at the same time window [14].
Moreover, pain associated with microglia and astro-
cyte activation occurs in EAE prior to the onset of
clinical signs [15, 16].
It is worthy of note that few studies to date have been
devoted to the investigation of this asymptomatic phase
of the disease. In order to elucidate very early molecular
alterations occurring in the CNS of EAE animals before
the clinical onset of the disease and to link tissue alter-
ations to potential CSF and plasma biomarkers, in the
present study, we investigated molecular mediators of
neuroinflammation and demyelination in the tissue (SC),
CSF, and plasma during early presymptomatic EAE using
high-throughput technologies for gene expression and
protein assays. The results indicate that the profile of
neuroinflammation and demyelination biomarkers is
dramatically changed during the early phase of EAE.
Consequently, we have identified the regulation of the
chemokine macrophage colony-stimulating factor (CSF1)
already 24 h after immunization, which indicates the
occurrence of microglia activation. Interestingly, we found
that a selective inhibition of CSF1R significantly reduced
the severity of the disease and prevented the relapse phase
in EAE rats, suggesting the importance of CSF1-CSF1R
signaling in microgliosis and inflammation in MS.
Methods
Animals, EAE induction, and disease follow-up
Dark agouti (DA) (Harlan, Italy) female rats, 151–167-g
body weight, were used in the first part of the study,
placed on ad libitum food and water, and housed three
per cage on a 12-h light/dark cycle. The DA rat model
of EAE mimics certain aspects of the clinical course of
the disease in people with RRMS [17–19], typified by
progressive, sustained demyelination, and associated
axonal loss [20, 21]. The disease onset in this strain
bears is characterized by neurological impairments,
manifested as a flaccid tail followed by an acute attack
with disturbed gait and paralysis. Most DA animals
recover spontaneously from paralysis and experience
remission and may then undergo one or more relapses.
A group of 42 rats was sensitized (considering group
composition and two extra animals) by a medium con-
taining 0.15 mg/ml guinea pig spinal cord tissue in
complete Freund’s adjuvant (CFA, Sigma, Saint Louse,
USA), 50% v/v, to which 5 mg/ml of heat-inactivated
Mycobacterium tuberculosis (Difco H37Ra, DB, Milan,
Italy) was added. Sensitization was performed by inject-
ing 100 μl in both hind pads. Control rats (n = 8) and
adjuvant-injected rats (CFA, 50% v/v, heat-inactivated M.
tuberculosis, 5 mg/ml) (n = 15) were used. The rats were
weighed daily and examined for clinical signs of EAE,
according to the following semi quantitative score for
neurological disability: 0 = no signs, 1 = loss of tail tone,
2 = mono or bilateral weakness of hind legs or middle
ataxia, 3 = ataxia or paralysis, 4 = severe hind legs paralysis,
and 5 = severe hind leg paralysis and urinary incontinence
[22]. In view of the animals’ disability, wet food was
included inside the cages to facilitate feeding. At 1, 5, 8, 11,
and 18 DPI, eight EAE rats were randomly sacrificed. From
each experimental group, five animals were used for prote-
omic and molecular biology experiments and three for
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morphology and immunohistochemistry. All animal proto-
cols described herein were carried out in accordance with
the European Community Council Directives (86/609/
EEC), approved by the intramural ethical committee for
animal experimentation of Bologna University and the
Ministry of Health (no. 158/2013-B) and comply with the
guidelines published in the NIH Guide for the Care and
Use of Laboratory Animals [23].
GW2580 treatment and CSF1R inhibition
In order to calculate the number of animals needed to
study the effect of the treatment with GW2580, we per-
formed a power analysis using the G*Power 3.1 software.
To reach a power of 0.9, based on retrospective analysis
of recent research done by others [24, 25], we needed a
minimum of n = 6 animals per experimental group.
The experiments were designed in compliance with
the ARRIVE guidelines, randomizing the procedures and
applying blinded analysis.
GW2580 (LC Laboratories, Boston, USA) was dis-
solved in 0.5% hydroxypropyl methylcellulose and
0.1% Tween 80 [26, 27]. The experimental groups
made of n = 6 animals each were as follows: vehicle
(0.5% hydroxypropyl methylcellulose/0.1% Tween 80);
control + GW2580; EAE; and EAE +GW2580. The rats
(control + GW2580 and EAE +GW2580 groups) were
under GW2580 treatment at 40 mg/kg once daily by oral
gavage using flexible plastic feeding tubes FTP-15-78-50
(Instech Laboratories, Netherlands) for 1 day prior and 11
consecutive days following the immunization. All animals
were weighed daily and the EAE and EAE +GW2580
groups were examined for clinical signs of EAE till the 18
DPI (last day of the experiment) following the semi quan-
titative score for neurological disability as already ex-
plained in the first part of the study. Animal protocols
described herein were carried out in accordance with the
European Community Council Directives (86/609/EEC),
approved by the intramural ethical committee for animal
experimentation of Bologna University and the Ministry
of Health (no. 607/2016-PR).
Histology and immunohistochemistry
On post-immunization days 1, 5, 8, 11, and 18, three rats
were scarified and the lumbar spinal cord (LSC) tissues
of the control, EAE, and adjuvant groups were fixed in
4% paraformaldehyde and picric acid and saturated
aqueous solution in 0.1 M Sörensen buffer pH 7 for
24 h and then washed with 5% sucrose solution every
day till the fixative was completely removed. The tissues
were frozen with CO2 gas and kept at −80 °C until proc-
essed. Coronal sections (14-μm thickness) were then
prepared (Microm HN550, Bio-Optica, Milan, Italy) and
processed for morphological studies. For immunohisto-
chemistry, the sections were first rehydrated and then
incubated for 1 h with PBS–0.3% Triton X-100, 2% normal
serum goat, and 1% BSA, followed by incubation with the
primary antibodies diluted in the pre-absorption solution
overnight at 4°C. The primary antibodies and dilutions used
were as follows: rabbit anti-CD44 (1:100, Cluster of differ-
entiation 44, Acris Antibodies, Inc, San Diego, USA), rabbit
anti-CD163 (1:100, Cluster of differentiation 163, Bioss
Inc, Woburn, USA), mouse anti-CD86 (1:250, Cluster
of differentiation 86, Novus Biological Europe, Cam-
bridge, UK), mouse anti-NF200 (1:200, Neurofilament, Sigma,
Saint Louse, USA), rabbit anti CSF1 (1:100, colony-
stimulating factor 1, Novus Biological), mouse anti-OX42
(1:250, AbD Serotec Inc., Raleigh, USA), mouse anti-NG2
(1:100, membrane-spanning chondroitin sulfate proteoglycan,
Millipore, Merck S.p.a., Milan, Italy), mouse anti-
CNPase (1:250, 2′, 3′-cyclic nucleotide 3′-phosphodiester-
ase, Millipore, Merck S.p.a., Milan, Italy), rabbit anti-GFAP
(1:500, glial fibrillary acidic protein, Dako, Milan, Italy), and
mouse anti-GFAP (1:500, Sigma, Saint Louse, USA). Fluor-
oMyelin™ Fluorescence Myelin Staining (Molecular Probes,
Eugene, OR) was also performed to stain the myelin
sheaths, following the manufacturer’s specifications. After
rinsing in PBS, the sections were incubated at 37 °C for
30 min with the secondary antibodies: DyLight488-
conjugated affinity-pure goat anti-mouse IgG (Thermo-
Scientific, Milano, Italy), Rhodamine Red™-X-conjugated
affinity-pure donkey anti-rabbit IgG (Jackson Immunore-
search, West Grove, PA, USA), DyLight488-conjugated
affinity-pure donkey anti-rabbit IgG (ThermoScientific,
Milano, Italy), and Red™-X-conjugated affinity-pure donkey
anti-goat IgG (Jackson Immunoresearch, West Grove, PA,
USA) diluted in PBS–0.3% Triton X-100, 1:100. The
sections were then rinsed in PBS and mounted in phenyl-
enediamine solution (0.1% 1,4-phenylenediamine, 50% gly-
cerine, carbonate/bicarbonate buffer pH 8.6, Sigma, Saint
Louse, USA). The control slices were incubated with the
secondary antibodies only and processed in parallel. Images
were captured using a Nikon Eclipse E600 microscope
equipped with digital CCD camera Q Imaging Retiga-
2000RV (Q Imaging, Surrey, BC, Canada). To analyze the
inflammatory infiltration, the sections were stained with
toluidine blue and evaluated on three replicate sections per
animal, counting the number and severity of cellular infil-
trates over each whole coronal section. Cellular infiltrates
were scored as follows: 0, none; 1, a few inflammatory cells;
2, organization of perivascular infiltrates; and 3, increasing
severity of perivascular cuffing with extension into the
adjacent tissue [28]. The inflammation score derives from
the sum of infiltration scores in each cellular infiltrate.
Spinal cord mRNA analysis
At post-immunization days 1, 5, 8, 11, and 18, five rats
were sacrificed and the total LSC was dissected, snap
frozen, and stored at −80 °C until used.
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The total RNA was prepared from the spinal cord using
QIAzol Reagent, cleaned with RNeasy Mini kit (Qiagen;
Milano- Italy), and eluted in RNase Free Water, and purity
and concentration were evaluated by spectrophotometry
using NanoDrop ND-2000 (ThermoScientific, Milano,
Italy). Complementary DNA (cDNA) synthesis was per-
formed using RT2 First Strand kit following the manufac-
turer’s instructions. In brief, after incubation for 5 min at
42 °C with genomic DNA elimination mix in order to
avoid any DNA contamination, a reverse-transcription
mix of BC3, P2, RE2, and H2O was used and the
transcription was performed in a final volume of 20 μl by
heating first at 42 °C for 15 min, then at 95 °C for 5 min.
Real-time PCR amplification was performed using the
Stratagene Mx3005P multiplex quantitative PCR system
(Agilent Technologies). The expression of genes involved
in MS progression was carried out using RT2 SYBR Green
qPCR Mastermix and the Multiple Sclerosis RT2 Profiler
PCR Array (Qiagen). The genes are grouped according
to the following: T cell activation/signaling, adaptive
immunity, cytokine/chemokine inflammation, demyelin-
ation, and cellular stress. The raw data obtained was
uploaded into GeneGlobe Data Analysis software (SABios-
ciences, Qiagen) for analysis. Relative quantification of
messenger RNA (mRNA) expression was calculated using
the comparative cycle threshold (CT) method and is
expressed as Log2 fold change of expression. The fold
change (2^(−Delta Delta Ct)) is the normalized gene
expression (2^(−Delta Ct)) in the test sample divided by
the normalized gene expression (2^(−Delta Ct)) in the
control sample.
CSF and plasma biomarker analysis
CSF sampling was adapted from the method of Liu and
Duff [29]. Briefly, the rats were anesthetized by iso-
flurane inhalation (Gas Anesthesia System-21100, Ugo
Basile, Varese, Italy) and placed prone on the stereotaxic
instrument letting the body of the rat laid down. A sagit-
tal incision of the skin was made below the occiput, and
the subcutaneous tissue and neck muscles through the
midline were separated and held apart using a microre-
tractor. The dura mater of the cisterna magna was then
penetrated by an 8-cm long glass capillary, which had a
narrowed tip with an inner diameter of about 0.5 mm so
that the CSF flowed into the capillary. After collection,
each sample was centrifuged at 2000×g for 10 min at
4 °C, and the supernatant aliquoted and stored at −80 °C
for biochemical assays.
Blood was collected from the abdominal aorta in
EDTA-K2 Vacuntainer tubes and centrifuged at 3000×g
for 10 min at 4 °C, and the plasma was collected,
aliquoted, and stored at −80 °C until used.
Proteins known to play key roles in neuroinflamma-
tion pathways were selected. For this purpose, Bio-Plex
Pro™ Rat Cytokine 24-plex Assay (Bio-Rad; Milano, Italy)
was used. The kit included EPO, G-CSF (CSF3), GM-
CSF (CSF2), GRO/KC, IFN-γ, IL-1α, IL-1β, IL-2, IL-4,
IL-5, IL-6, IL-7, IL-10, IL-12p70, IL-13, IL-17A, IL-18,
M-CSF (CSF1), MCP-1 (CCL2), MIP-1α (CCL3), MIP-
3α (CCL20), RANTES (CCL5), TNF-α, and VEGF.
The simultaneous quantification of the different pro-
teins in CSF and plasma was performed using xMAP
technology and a MAGPIX Luminex platform. This
technology makes use of different populations of color-
coded beads of monoclonal antibodies specific to a
particular protein, thus allowing simultaneous capture
and detection of specific analytes from a sample. All the
beads from each set are read off, which further validates
the results. Using this process, xMAP Technology allows
multiplexing of up to 50 unique bioassays within a single
sample, both rapidly and precisely [30, 31]. In brief, after
the incubation of a specific monoclonal antibody conju-
gated bead population with 50 μl of CSF/plasma samples
for 1 h at RT, washed beads were incubated with
detection antibody solution at RT for 30 min, then with
the streptavidin–phycoerythrin conjugated solution (RT,
10 min). After washing, beads were resuspended in the
assay buffer, shaken for 1 min and then a reading
performed on the MAGPIX instrument. The results
were analyzed with xPONENT 4.2 ® software and
expressed as pg/ml.
Statistical analysis
Student’s t test to compare means of two experimental
groups, one-way ANOVA followed by Dunnett’s multiple
comparison tests, and two-way ANOVA followed by
Bonferroni post-test were used. Data are presented as
mean ± standard error of the mean, and significance was
set at P ≤ 0.05. All statistical analyses were performed
using GraphPad Prism 6.0 (GraphPad Software).
For the normalization of gene expression on the RT2
PCR Profiler Array, five housekeeping genes, ribosomal
protein, large, P1, hypoxanthine phosphoribosyltransfer-
ase 1, ribosomal protein L13A, lactate dehydrogenase A,
and actin beta were used. The CT was determined for
each sample and normalized to the average CT of the
five housekeeping genes. A comparative CT method was
used to calculate relative gene expression. Data are
represented as Log2 fold change relative to control. The
P values were calculated on the basis of a Student’s t test
of the replicate 2^(–Delta Ct) values for each gene in the
control group and treatment groups, and P values less
than 0.05 was considered significant.
Results
Clinical profile and histopathology
The clinical profile of EAE is reported in Fig. 1a, b in
which the clinical score (a) and body weight graphs (b)
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Fig. 1 (See legend on next page.)
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are shown. Clinical signs of neurological disabilities in
EAE started at 7–8 DPI and reached the higher score at
11 DPI (acute phase). A remission phase is then ob-
served, from 12 to 15 DPI, followed by a rapid increase
in the clinical score (relapsing phase). Figure 1b shows
the body weight gain, which decreases in EAE groups
from 2 DPI compared to the control group (P < 0.001).
A difference between EAE and adjuvant groups is also
observed from 7 to 12 DPI (P = 0.0139), in close corres-
pondence with the evolution of the symptoms of the
disorder, which is followed by a partial recovery.
Histopathology was performed in the LSC at each time
point investigated, focusing on inflammation and demye-
lination. Representative images of toluidine blue staining
(C-H) and immunofluorescence visualization of OX42-
IR microglia cells (I-L), GFAP-IR astrocytes (M-P), and
myelin (T-W) are reported in Fig. 1. Toluidine staining
illustrates the massive cellular infiltrate starting from
11 DPI. The semiquantitative evaluation reveals a se-
vere and diffuse cellular infiltrate (P < 0.0001) in the
LSC at the acute and the remission phases (11, 18 DPI)
(Fig. 1q). Significantly, microglial reaction starts at 8
DPI (P = 0.0001) (Fig. 1r), when OX42-IR cells take on
a rounder morphology (see high-magnification inserts
in Fig. 1i, j, EAE t8, compared to the control) and con-
verge around blood vessels, reaching a peak at 11 DPI
(P < 0.0001). The astroglial reaction was also analyzed
by GFAP-immunostaining and a higher immunoreactiv-
ity was observed at 8 DPI (P = 0.0005) (Fig. 1m, n,
control, compared to EAE t8). Demyelination signs
appear at 8 DPI as revealed by the slight decrease in
FluoroMyelin staining intensity in the gracile fasciculus
(gr) of the LSC, (Fig. 1t, u, control, compared to EAE
t8; see arrows), which is very extensive at 11 DPI
(Fig. 1t, v, EAE t11, compared to the control; see plus)
and has partially recovered at 18 DPI (Fig. 1t, w,
control, compared to EAE t18; see asterisks).
Regulation of inflammatory mediators in SC during early
asymptomatic EAE
The mRNA expression of genes that encode for T cell
activation/signaling, adaptive immunity, cytokines/che-
mokines, and cellular stress involved in neuroinflamma-
tion and demyelination processes were studied in the SC
by real-time PCR. The complete list of investigated
genes is presented in Fig. 2. For biological averaging and
variance reduction, samples from each group were
pooled for microarray experiments, in fact, for very
small designs, pooling dramatically improves accuracy
[32–34]. The results from the different groups are
presented in a clustergram that performs non-supervised
hierarchical clustering to display a heat map with dendro-
grams indicating co-regulated genes across groups, criteria
for significance are reported in the table of magnitude
gene expression (Fig. 2). Several pro-inflammatory cyto-
kines and chemokines such as IL-1β and CCL12 were
highly up-regulated in the SC at 8 DPI and reached a peak
at 11 DPI. IFN-γ, CXCL11, and LTA were the most up-
regulated genes, showing more than 22 Log2 fold change
compared to the controls at 8 DPI, around 115 at 11 DPI,
and more than 67 Log2 fold change at 18 DPI. The high-
est up-regulation was observed for IFN-γ, 68.12 Log2 fold
change at 8 DPI, 179.15 at 11 DPI, and 98.7 at 18 DPI
(Fig. 2). Notably, ADAM17 and CSF1 mRNAs are strongly
down-regulated at 1 DPI. Most of the anti-inflammatory
cytokines and chemokines were down-regulated with a
profile opposite to that observed for the pro-inflammatory
ones (starting to decrease from 8 DPI), including VEGF,
SOD1, NTF3, APC, HEXB, while an up-regulation was
observed for some anti-inflammatory mediators such as
GPX1 and IL-10. With regard to genes involved in mye-
lination, a down-regulation starting from 8 DPI was
observed, including MAL, MBP and PMP22. To note, the
overexpression of IFN-γ mRNA in EAE in acute phase
(11 DPI) is the highest EAE-induced up-regulation ob-
served compared to the other inflammatory mediators
investigated (Fig. 2).
Inflammation biomarkers at plasma and CSF level are
regulated during early asymptomatic EAE
In order to evaluate the kinetics of inflammation bio-
markers during EAE, 24 cytokines and chemokines,
EPO, G-CSF (CSF3), GM-CSF (CSF2), GRO/KC, IFN-γ,
IL-1α, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-10, IL-12p70,
IL-13, IL-17A, IL-18, M-CSF (CSF1), MCP-1 (CCL2),
MIP-1α (CCL3), MIP-3α (CCL20), RANTES (CCL5),
TNF-α, and VEGF, were simultaneously quantified in
CSF samples at the different time points investigated
(See figure on previous page.)
Fig. 1 EAE clinical profile and histopathology. a The time-course of the neurological disability score of EAE animals is reported in the graph
(mean ± SD), showing the peak at day 11 (acute phase), the remission phase at day 16, and relapse at day 18. b The body weight gain in
experimental animals is reported in the graph (mean ± SD), revealing a significant difference between the control and EAE group. Statistical
analysis: one-way ANOVA, ****P < 0.0001. Toluidine blue staining of the lumbar spinal cord (c–h) massive cellular infiltrate starting from 11 DPI
(EAE t11) OX42-IR microglia staining (i–l). GFAP-immunostaining (m–p). q The semiquantitative evaluation of the inflammation score in the LSC.
r Immunoreactivity indicates that microglia activation starts at 8 DPI. s Astrocyte immunoreactivity starts at 8 DPI. Fluoromyelin staining (t–w) in
control (t); EAE t8 (u); EAE t11, the acute phase (v); and EAE t18, the remission-relapsing phase (w). Arrow in u indicate a partial demyelination at
8 DPI; plus in v indicates severe demyelination during the acute phase; asterisks in w indicate a partial recovery at 18 DPI. Statistical analysis:
one-way ANOVA and Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01, ***P < 0.001). t time
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(1, 5, 8, 11, and 18 DPI, Fig. 3a, c). IL-17A, IL-1β, TNF-α,
and IL-10 were significantly increased at 8 DPI in
EAE group compared to the control animals (P = 0.0412;
P = 0.0127; P = 0.0039; P = 0.0412, respectively), reaching
a peak at 11 DPI (P < 0.0001; P < 0.0001; P < 0.0001;
P = 0.0074, respectively) and decreasing again at 18
DPI (ns; P = 0.0035; P < 0.0001; P = 0.0128, respectively).
For both pro-inflammatory chemokines CCL2 and CCL3
and for the anti-inflammatory cytokines IL-5, the same
significant profile was observed, reaching a peak at 8
DPI (P < 0.0001; P = 0.001; P < 0.0001, respectively)
then starting to decrease starting from 11 DPI (P < 0.0001;
P = 0.0046; P < 0.0001, respectively). The levels of CCL20
and IL-6 were significantly increased in EAE animals only
at 8 DPI (P < 0.0001; P = 0.004, respectively) (Fig. 3).
Unpredictably, IFN-γ, IL-13, IL-2, IL-1α, IL-4, IL-
12p70, and GM-CSF were not detected at any of the
time points analyzed in the CSF in our experimental
conditions.
The different cytokines/chemokines quantified in
CSF were also simultaneously measured in plasma
samples (Fig. 3b, d) in order to both correlate with
CSF changes and to evaluate the peripheral effect of
adjuvant. IL-1β increased in EAE compared to con-
trol group of animals at 8 DPI (P = 0.0231). GM-CSF
was the only cytokine not detectable at any of the
time points analyzed, and no significant changes was
observed for the rest of the panel compared to the
control.
No significant variations between adjuvant and con-
trol groups were observed in CSF or plasma at the
investigated times.
Fig. 2 Inflammation genes mRNA expression level in the SC. The expression levels of mRNA of T cell activation/signaling, adaptive immunity,
and cytokine/chemokine inflammation and demyelination are reported in the clustergram, based on heat map with dendrograms, indicating the
co-regulated genes across groups. Red color for a gene indicates expression above the median, and green color indicates expression below the
median. The table presents differentially expressed genes. Statistical analysis was performed using Student’s t test of the replicate 2^(−Delta Ct)
values for each gene in the control group and treatment group; P < 0.05 was considered significant
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Immunohistochemical analysis
In order to elucidate the cell type producing the most
regulated biomarkers, double-labeling experiments were
performed in the LSC of the control and EAE animals.
Representative images from the control and EAE
animals at 8, 11, and 18 DPI are shown in Fig. 4. The
following markers were investigated: OX42 as marker
for microglia; CD86, as marker for M1 macrophages
Fig. 3 Cytokine/chemokine levels in CSF/plasma. The amount of IL-1b, IL-17A, IL-5, TNF-α, IL-6, MIP-3a (CCL20), IL-10, MCP-1 (CCL2), RANTES
(CCL5), and MIP-1a (CCL3) in CSF (a, c) and plasma (b, d) in the control, EAE, and adjuvant groups are reported. Results are presented as individual
values (pg/ml), and the mean ± SD is also shown. Statistical analysis: one-way ANOVA and Dunnett’s multiple comparison test (*P < 0.05, **P < 0.01,
***P < 0.001, ****P < 0.0001)
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phenotype; CD163, as marker for M2 macrophages
phenotype; CD44, as marker for T lymphocytes; NG2, as
marker for oligodendrocyte precursor cells (OPCs); and
CNPase, as marker for oligodendrocytes. Immunostain-
ing was quantified by a computerized procedure to
evaluate the immunoreactive area. As expected, the in-
crease in OX42-IR observed at 8 DPI corresponds to in-
creased expression of the M2 cytokine CD163 (Fig. 4a–d,
see plus in B, M), while the M1 macrophage marker CD86
showed the highest immunoreactive area at 11 DPI
(Fig. 4i–l, p). This activation was accompanied by an in-
crease in the CNPase immunoreactive (IR) area starting
from 8 DPI (Fig. 4e–h, n), which partially contrasts with
the FluoroMyelin staining results (Fig. 1t–w). In the con-
trol group, CD44 was expressed by oligodendrocytes
(Fig. 4e; see arrows), while this co-localization was no
longer present in the EAE animals at 8, 11, and 18 DPI
(Fig. 4f; see asterisk). The highest up-regulation of the
different markers verified in the white matter was
detected in the acute phase of EAE (Fig. 4c, g, and
k), where also a significant up-regulation of CD163
(P = 0.0016), CNPase (P = 0.0197), CD44 (P = 0.0005),
and CD86-IR (P < 0.0001) areas were observed at 11
DPI (Fig. 4m, n, o, and p, respectively).
No significant results were observed in EAE t1,
EAE t5, and adjuvant experimental groups (results
not shown).
CSF1 regulation in early presymptomatic EAE
Going one step deeper into biomarker regulation at the
early phase of EAE, it was found that the pro-
inflammatory mediator CSF1 (The CSF-1R is a member
of the platelet-derived growth factor receptor (PDGFR)
family of class III receptor tyrosine kinases that includes
PDGFRα/β, stem cell factor receptor (c-Kit), and Flt3/
Flk2) [35] was regulated starting from 1 DPI in EAE
Fig. 4 Immunohistochemistry analysis. Double immunostaining of OX42/CD163, CNPase/CD44 and CD86/NG2 in the lumbar spinal cord of
control and EAE rats. a–d Double labeling for microglial cells marker (OX42) and M2 macrophages marker (CD163) in the white matter of control
(a) and EAE experimental groups: 8, 11, and 18 DPI (b–d). Plus in b indicates the activated microglia expressing CD163. e–h Double labeling for
oligodendrocyte marker (CNPase) and T lymphocyte marker (CD44) (see also the included high-power magnifications). CD44 is expressed by
oligodendrocytes in control. Arrows in e indicate co-localization, although this expression changed at 8 DPI in f. i–l Double labeling for oligodendrocyte
precursor cells (NG2) and M1 macrophages marker (CD86). The immunoreactive area of CD163 (m), CNPase (n), CD44 (o), and CD86 (p) in EAE rats
compared to controls. Statistical analysis: one-way ANOVA and Dunnett’s multiple comparison test (*P< 0.05, **P< 0.01, ***P< 0.001, ****P< 0.0001)
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group compared to the control in all the biological
samples analyzed (Fig. 5a). In plasma, CSF1 was signifi-
cantly up-regulated only at 1 DPI (P = 0.0006), then
continuously decreased till the last time point studied,
18 DPI (Fig. 6b), while in CSF, CSF1 level started to
decrease at 1 DPI, becoming significant at 11 and 18
DPI (P < 0.0001, P < 0.0001) (Fig. 5c). Notably, CSF1-IR
in the tissue also increased starting from 1 DPI (P = 0.0003)
(Fig. 5e, k), then decreased at 5 and 8 DPI (Fig. 5g, h)
ultimately reaching the highest immunoreactivity at 11 DPI
(P < 0.0001) (Fig. 5i, k). The mRNA expression of CSF1
gene in SC was also analyzed (Fig. 2), and a down-
regulation at 1 and 11 DPI was observed (Fig. 5d). In the
attempt to identify the CSF1-producing cells at 1 and 11
DPI, double-labeling immunostaining of CSF1 with CNPase
and GFAP was performed in the LSC (Fig. 5l–o). Figure 6n,
o shows that CSF1 is constitutively expressed by astrocytes
not only in the EAE animals but also in the control (results
not shown). Interestingly, CSF1 was expressed by oligoden-
drocytes at 1 DPI in EAE (Fig. 5l), while this expression is
no longer present as from 11 DPI (Fig. 5m).
Functional pathway and network analysis
In an exploratory study, a pathway analysis approach of
the different proteins derived from the most early regu-
lated genes at 8 DPI was implemented. This time point
corresponds to the beginning of the regulation of genes
in the CNS, while cellular infiltrates are not yet present
and clinical signs start to appear. We proceed through
the web-software STRING 10.0 (http://string-db.org/)
and Gene Ontology databases. The protein–protein
interaction analysis (both physical and functional inter-
actions) was performed using default parameters (high
confidence, 0.7) and R.norvegicus as the organism of
interest. The software allows the net of interactions
including other proteins closely linked to the one
analyzed to be extended, in order to obtain a better un-
derstanding of the possible pathways affected by EAE in
DA rats at early onset. The analysis showed that almost
all the proteins deriving from genes of interest (except
for the CXC family) did not directly interact with each
other (Fig. 6a). The extended network (indirect protein–
protein interactions) showed that those proteins were
connected in four clusters according to their involve-
ment in the biological process (autoimmune disease),
situating STAT1 (signal transducers and activators of
transcription), FLT1 (vascular endothelial growth factor
receptor 1), and TRAF6 (TNF receptor associated factor)
as nodes of the extended net linking the different groups
(Fig. 6b). To gain further insight into the biological
significance of those clusters in MS, an enrichment ana-
lysis using Gene Ontology was performed. It was found
that these four clusters consist of a Wnt signaling path-
way (the green cluster), a cytokine-mediated signaling
pathway (the yellow cluster), T cell chemotaxis (the blue
cluster), and positive regulation of mitogen-activated
protein tyrosine kinase (MAPK) (the red cluster). Not-
ably, CSF1 takes part of MAPK cluster.
Effects of selective inhibition of CSF1R activity on the
clinical score of EAE animals
Since the peculiar temporal expression pattern of CSF1
in particular in the very early phase of the disease, the
tyrosine kinase activity of CSF1R was inhibited by the
oral administration of GW2580. GW2580 is a highly
selective inhibitor of the c-FMS kinase, and through this
pathway, this small molecule blocks CSF1 signaling.
Treatment started 1 day before the immunization and
till 11 DPI. The clinical profiles of the disease in EAE,
EAE + GW2580, control + GW2580, and vehicle groups
of animals are reported in Fig. 7, in which the clinical
score (a) and body weight graphs (b) are shown. Clinical
signs of the neurological disabilities in EAE were the
same as reported in the first group of animals included
in our study (Fig. 1a), which prove the reproducibility of
the model. While the clinical signs started at 6–7 DPI in
the EAE group, a delay in the appearance of the neuro-
logical disability was observed in the EAE + GW2580
group. The acute phase was at 11–12 DPI with a
maximum score of 5, while a significant reduction of the
severity of the disease was observed in the EAE +
GW2580 group (P < 0.001) with a maximum score of
2.8. Interestingly, the EAE +GW2580 animals did not
show any relapse phase (P < 0.001) and after the acute
phase, they were recovering till the 18 DPI, last day of
the experiment (P < 0.001). Figure 7b shows the body
weight gain. A decrease was observed in the EAE +
GW2580 groups from 2 DPI compared to the GW2580
animals (P < 0.001), which is the same profile of the body
weight loss observed in the EAE group but less severe,
in close correspondence with the evolution of the symp-
toms of the disorder, which is followed by a recovery.
We also calculated the cumulative disability index,
reported in Fig. 7c, observed in EAE compared to the
EAE + GW2580 groups (P < 0.001).
Discussion
The aim of this study was to investigate the expression
profile of molecules involved in inflammation and de-
myelination in the very early presymptomatic phase of
EAE induced by active immunization in female DA rats
by comparing the tissue (spinal cord), CSF, and plasma.
It was previously demonstrated that in the acute phase
of this model, a massive infiltration of inflammatory cells
and extensive demyelination were observed in the spinal
cord [36–38]. Samples collected at symptom-free times
(1 and 5 DPI) and at the symptom onset (8 DPI), peak
(11 DPI), and relapse (18 DPI) were then examined
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Fig. 5 Early regulation of CSF1 in EAE. a Schematic illustration of CSF1 regulation in all the biological samples analyzed on Excel: the XY scatter
option is chosen and under the chart subtypes, the option connecting the points with smooth lines with markers is selected. The amount of CSF1
in plasma (b) and CSF (c) in the control, EAE, and adjuvant groups are reported. Results are presented as individual values (pg/ml), and the mean
± SD is also shown. d The expression level of mRNA of CSF1 is reported in the clustergram, based on heat map with dendrograms, indicating the
co-regulation across the different groups (e–j) k CSF1-immunostaining in the white matter of control and EAE experimental groups: 1, 5, 8, 11,
and 18 DPI. The immunoreactive area of CSF1 in EAE rats compared to controls. Double labeling for CSF1 and oligodendrocytes marker (CNPase)
and GFAP in the EAE group 1 and 11 DPI (l, m and n, o, consecutively). Statistical analysis: one-way ANOVA and Dunnett’s multiple comparison
test (*P < 0.05, ***P < 0.001, ****P < 0.0001)
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using high-throughput technologies together with bio-
informatic analysis for molecule and pathway identifica-
tion in CNS tissue and biological fluids.
At mRNA level (spinal cord tissue), T cell activation/
signaling, adaptive immunity, cytokine/chemokine in-
flammation, demyelination, and cellular stress were
analyzed, thereby including astroglial and microglial
markers. Microglia markers refer to the “resting state”
(M0); to inflammatory microglia (M1 polarization)
producing numerous pro-inflammatory cytokines/chemo-
kines; and to anti-inflammatory microglia (M2 polarization),
which triggers them to endorse regeneration and eliminate
debris [39–41]. The most significant results were verified by
means of double-labeling immunohistochemistry. At pro-
tein level in CSF and plasma, 24 cytokines were analyzed.
Our first important result is that an early regulation of
most of the inflammatory and demyelinating biomarkers
was observed as soon as symptoms appear (8 DPI) but
Fig. 7 Effects of selective inhibition of CSF1R activity on the disease progression. a. Time-course of the neurological disability score of EAE and
EAE + GW2580 animals is reported in the graph (mean ± SD), showing the peak at day 11 (acute phase), the remission phase at day 16, and
relapse at day 18 for EAE animals while a delayed and reduced clinical score was observed for EAE + GW2580 group. b The body weight gain
(mean ± SD) is reported in the graph (mean ± SD), enlightening a significant difference between GW2580 and EAE + GW2580 group. c Cumulative
disability index. Statistical analysis: a, b two-way ANOVA and Bonferroni post-test (***P < 0.001); c one-way ANOVA, ****P < 0.0001
Fig. 6 Functional pathway and network analysis. a Illustration of protein interactions of the most regulated gene at 8 DPI upon querying the
STRING 10.0 protein network (evidence view). b The extended net (high confidence, 0.7). Nodes represent proteins; same node colors indicate
membership of the same cluster, and different line colors denote the type of evidence for the interaction
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before the disease peak (11 DPI). Molecular markers of
microglial activation toward a phagocytic phenotype are
found (8 DPI), when also astrocyte hypertrophy is
observed. The highest regulation of these markers is
observed when symptoms peak (11 DPI, acute phase)
and then partially recover at relapse (18 DPI). Signifi-
cantly, microglia and astrocytes were activated early in
the EAE animals by 8 DPI. Indeed, almost all the cyto-
kines/chemokines shift their expression at 8 DPI in
plasma, CSF, and even in the SC. In particular, a higher
regulation of CCL2, TNF-α, and IL-1β was found, pos-
sibly indicating the initiation of BBB breakdown. Indeed,
it has been demonstrated that the CCL2-CNS level can
be induced by the pro-inflammatory cytokine IFN-γ,
TNF-α, and IL-1β and does affect the BBB integrity and
attract monocytes to the CNS [42, 43]. Interestingly, we
found that the anti-inflammatory biomarkers, IL-5 and
IL10, have the same profile of expression as the pro-
inflammatory mediators, revealing that both “M1” and
“M2” polarization is present at the same time during
EAE. Actually, very recent studies have shown that micro-
glia/macrophages simultaneously express both “M1” and
“M2” phenotypic markers in brain trauma, suggesting that
these cells display a mixed phenotype due to the fact they
cannot adequately switch to a polarized “M1-only” or
“M2-only” phenotype [44, 45].
Using a functional pathway analysis tool, Gene Ontol-
ogy and Enrichment Analysis, four possible pathways
were indicated as affording suggestive evidence of being
associated with the early phase of MS: the Wnt signaling
pathway, the cytokine-mediated signaling pathway, the T
cell chemotaxis pathway, and MAPK. Significantly, Wnt
signaling has been recognized as the central tenet in the
development and regeneration of myelin in the CNS
[46]. Chronic activation of canonical Wnt signaling in
oligodendrocyte precursors results in delayed develop-
mental and regenerative myelination [47, 48]. Interest-
ingly, IL-6, which belongs to the MAPK pathway, was
detected only at 8 DPI. Besides, IL-17A, which is
secreted by T helper-17 which contributes to pathogen-
esis in MS and EAE [49], started to be regulated at 8
DPI, confirming that IL-6 promotes T cell development
at 8 DPI. Indeed, it has been shown that IL-6-deficient
mice were resistant to EAE because they fail to induce
CNS–T helper-17 cells [50].
Our second major result is that the colony-stimulating
factor CSF1, part also of MAPK pathway, was regulated
at 1 DPI in EAE groups compared to the control, not
only in the plasma but also in CSF and SC. CSF1, is an
integral tyrosine kinase transmembrane receptor and
signals through its receptor CSF1R (also known as c-
FMS) to regulate the differentiation, proliferation, and
recruitment of microglia [51, 52]. Thus, our data indi-
cate that the first sign of immunological response in
EAE occurs in the CNS already 24 h after immunization
and plasma biomarker could reflect microglia activation
in the tissue. It was then attempted to identify the cell
type producing CSF1. It was found that CSF1 at 1 DPI is
expressed by oligodendrocytes and astrocytes in the EAE
animals, while in the acute phase (11 DPI), only astro-
cytes express CSF1. However, it was also seen that CSF1
is expressed by GFAP-positive cells in control, adjuvant-
injected, and intact animal. Moreover, we found that the
treatment with GW2580, a selective inhibitor of CSF1R,
delayed the onset of the disease, significantly reduced the
clinical severity and surprisingly prevented the relapse
phase even though the treatment was performed till the
11 DPI, thus suggesting the CSF1 is a major molecular
regulator in the very early phases of EAE. To our know-
ledge, our results provide the first evidence of the very
early regulation of CSF1 in EAE and on a major role of
CSF1-mediated events in EAE onset and progression.
A major question arising from this result is the cell
type responsible for this very early effect. The CSF1
receptor (CSF1R), encoded by the proto-oncogene c-fms
[53, 54] and having CSF1 and IL-34 as natural ligands
[55], is expressed by several cell types, including macro-
phages and microglia [56]. In the brain, it has been
confirmed that under normal conditions, microglia are
the only cell type that expresses the CSF1R [57, 58].
Several lines of evidence suggest that microglial ac-
tivation is mediated by the binding of CSF1 to CSF1R,
which triggers the release of inflammatory cytokines
[59, 60]. A role of CSF1 in microglial activation and
disease progression has been described in several models
of injury and neurodegenerative diseases, but in few of
them, the responsible cell type has been identified. In
neuropathic pain induced by peripheral nerve injury,
CSF1 is produced and retrograde transported to the spinal
cord by sensory neurons [61]. In the mouse model of
amyotrophic lateral sclerosis, the positive effects of
GW2580 has been attributed to the attenuation of macro-
phages infiltration of the peripheral nerve [62]. In an
Alzheimer’s mouse model, prolonged treatment with
GW2580 directly target microglia regulating cytokines
production and also improving the functional outcome
[25]. When used in EAE starting from 10 DPI, GW2580
reduces the proportion of peripheral macrophages, also
decreasing the number of inflammatory foci in the CNS
[63]. This effect has at least partially attributed to the
repression of the autocrine signaling of inflammatory mac-
rophages and microglia, leading to the reduction of neu-
roinflammatory cytokines and chemokines [57, 64, 65],
suggesting that targeting tyrosine kinase receptors such as
c-Fms and PDGFR could prevent the development of the
disease by enhancing BBB integrity [66].
According to our results, it could thus be speculated
that CSF1-CSF1R signaling plays an important role in
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not only the early phase of EAE but also all along the
disease progression. CSF1 could be so a good trigger for
microglial activation and subsequent induction of neu-
roinflammation, and its increase could be detected in
biological fluids including plasma. Further studies will
elucidate the mechanism of this early microglial activa-
tion, also in view of possible therapeutic implications. In
fact, the therapeutic potential of the CSF1R kinase
inhibitor has been explored in many pathologies such as
cancer, bone disease, inflammatory diseases, and other
autoimmune disorders, and so several CSF1R tyrosine
kinase inhibitors are under development for clinical
applications [67–70].
Conclusions
In the attempt to elucidate still elusive aspects of multiple
sclerosis (MS) pathogenesis, we performed a time-course
study in experimental allergic encephalomyelitis (EAE),
the most widely used MS rodent model, focusing on the
presymptomatic phase. By investigating neuroinflamma-
tion and demyelination biomarkers in the tissue, CSF, and
plasma using high-throughput technology and bioinfor-
matics analysis, we discovered the very early regulation of
the chemokine colony-stimulating factor 1 (CSF1), which
indicates the occurrence of microglia activation already
1 day after immunization. The selective inhibition of
CSF1R decreased EAE clinical severity and prevents the
relapse phase suggesting the importance of CSF1-CSF1R
signaling in microgliosis and inflammation in MS.
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